Abnormal tumor microenvironment and immune escape in multiple myeloma (MM) are associated with regulatory T cells (Tregs), which play an important role in maintaining self-tolerance and regulating the overall immune response to infection or tumor cells.
The present definition of complete remission (CR) in myeloma is not adequate. The definition is mainly based on measuring the secreted product of myeloma cells (M protein), which has a high interpatient and intrapatient variability, rather than on direct measurement of the remaining tumor load....
What are the effects of drugs on Treg cells in multiple myeloma, and what are the applications of treg cells in therapy? Introduction Multiple myeloma (MM) is the most common form of plasma cell malignancy, accounting for about 1.7% of all malignant tumors [1]. Although the use of a vari...
And this is a passion of mine, Alana, just to have pharmacists at a point where they are seeing patients, and they are making that impact. I think it’s on every single aspect of the care team. So, when you can have a pharmacist that's in ...
This has led to the consideration of CAR-T therapy earlier in the course of disease for myeloma, when T cells are potentially healthier and the myeloma is less aggressive. To address the question of earlier use of CAR-T therapy, several trials are either ongoing or planned, and results ...
therapy outcome. The prognostic utility of multicolor flow cytometry for assessing MRD in patients with acute lymphoblastic leukaemia and in acute myeloid leukaemia has been established.13MRD negativity assessment is considered a positive predictor of good long-term prognosis in multiple myeloma as well....